Partners

OUR PARTNERS

helping us to achieve our targets

Sigmathera has established strong partnerships and business relations in order to reach its targets for all possible applications of SIT161 and to offer this way novel and efficient solutions in the treatment & prevention of neurodegenerative diseases

European Union’s Horizon 2020 research and innovation programme 

  • This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No NeuroPa - 886169 
  • SigmaThera was awarded by the European Union’s Horizon 2020 research and innovation programme with the "Seal of Excellence" following evaluation by an international panel of independent experts and WAS SCORED AS A HIGH-QUALITY PROJECT PROPOSAL IN A HIGHLY COMPETITIVE EVALUATION PROCESS*
    * This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria (excellence, impact, quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020.

DHUNE, our Partner for NDDs. 
Excellence Center for NDDs and aging

  • DHUNE's mission is to build bridges between basic research, clinical research, social science, neuroscience, neuroimaging teams, education and private companies involved in the treatment of neurodegenerative diseases. 
  • The programme mobilizes a large concentration of multidisciplinary experts with a common goal: the fight against neurodegenerative diseases to achieve concrete results in less than 5 years. 
  • DHUNE established several partnering with patient and caregiver associations (France Alzheimer, CISS, France Parkinson, PACASEP, UNISEP, and others. 
  • Providing behavior, biochemistry and histology data.
  • DHUNE from the full support of industrial partners as well as big pharmaceutical companies (Ipsen, Sanofi) and has established strong links with most companies concerned with neurodegenerative diseases in the biomedical (Medtronic, Boston Scientific, Siemens, GE) and pharmaceutical (Roche, Novartis, GSK, Servier, Teva, Astra Zeneca, Lundbeck, J&J, Boehringer Ingelheim, Eli Lilly). 

The Neuroscience Institute of Montpellier, INSERM UMR1051, SAINT ELOI Hospital, Monpellier, France, Dr. Cédric Raoul

  • Priority of research to discover the causes of the disease and new treatments.
  • INSERM U105: Dr. Raoul, Neurobiology.

Best key opinion leaders in neurology identified for our clinical trials

  • We have approached the best opinion leaders for Alzheimer's disease and Amyotrophic lateral sclerosis for defining the protocols of clinical trials.
  • Professor Olivier Blin and Professeur Matthieu Ceccaldi at La Timone Hospital in Marseille and also Professor Jacques Touchon at La Colombière Hospital in Montpellier will be in charge of Alzheimer's disease studies. 
  • Concerning Amyotrophic Lateral Sclerosis, Professors William Camu at Saint Eloi Hospital in Montpellier and Shahram Attariam at La Timone Hospital in Marseille know SIT161 and are ready to start working with our product.

SigmaThera is part of Eurobiomed, a catalyst of excellence in the health sector in Southern France

  • EUROBIOMED leads territorial initiatives, provides resources and offers solutions for businesses and research organisations. EUROBIOMED helps them innovate, finance, develop and achieve their strategic and business objectives to ultimately improve life through innovations in health.
  • Founded in 2009 by regional stakeholders, EUROBIOMED tops European rankings in all stages of innovation: education, basic research, translational and clinical research, technological innovation centers, start-ups and Industrial success stories.
  • Together, the + 270 EUROBIOMED members from about 225 different companies are a driving force in regional development (with 172 projects, representing 718 million EUR of investment and 700 direct jobs) and a source of solutions for millions of patients coping with serious conditions such as cancer, chronic inflammatory disease, infectious and (re)emerging diseases, neurological diseases, and rare diseases.
  • EUROBIOMED provides resources and offers solutions for businesses and research organisations in the health sector to help them innovate, finance, develop and achieve their strategic and business objectives to ultimately improve the treatment and the lives of patients.

Amylgen was founded in 2009 and established as one of the French CRO leaders

  • CRO proposing the screening of molecules on rodent models of neurodegenerative and psychiatric diseases (Alzheimer's, Parkinson's, schizophrenia, depression, addiction, anxiety)
  • Providing behaviour, biochemistry and histology data.
  • Testing of several experimental groups in the same study and providing a first proof of concept of the efficacy of tested molecules in vivo.

The Research Network Ltd was founded in 2011 and provides Pharmaceutical R&D scientific consultancy

  • Integrated team of scientific consultants with expertise in small molecules and biotherapeutics.
  • Scientific leadership in Strategy, Design, Implementation,
  • New Therapeutic Venture Creation and support.
  • Integrated expert due diligence, project delivery and management in therapeutic areas.
  • Clients are major pharmaceutical and biotechnology companies as well as academic and charitably funded research groups.

Catalyze, our partner for grant applications. 
Help leading researchers
and companies secure funding for biomedical and healthcare innovations

  • Catalyze, a market leader in obtaining funding for biomedical and healthcare innovations, as well as for projects in the related ICT, eHealth, and big data fields. 
  • Catalyze help leading researchers and companies secure financing for ambitious R&D projects, from early-stage pre-clinical research up to clinical stage development. 
  • Through their services, they strive to contribute to the development of breakthrough products that serve an unmet medical need. 
  • Catalyze commit themselves to design the highest quality projects and be successful in securing funding to realize their clients’ strategic and business objectives.
  • Catalyze have raised + 400 million Euro in funding with a strong track record raising funding through, but not limited to, HORIZON2020, Eurostars, NIH, EuroTransBio, IMI, ERC, ERA-NET, EFRO, regional funds, and patient organizations. 

Mintz New York, our Patent Attorneys. Built on excellence, driven by change

  • The Intellectual Property practice at Mintz with its experienced IP attorneys help entrepreneurs, universities, and companies to acquire, protect, and enforce patent rights for their cutting-edge advancements.
  • Leading Law Firm for Collaboration 2017/BTI Consulting Group: The firm is one of only 54 law firms nationally to be recognized as highly collaborative by corporate counsel.
  • Best Law Firms 2019: U.S. News & World Report - Best Lawyers: Mintz is recognized as a top tier firm in the annual “Best Law Firms” rankings.
  • Chambers USA 2018: 48 Mintz attorneys and 19 practice areas are ranked among the legal profession’s leaders in the 2018 edition.
  • AmLaw 100 American Lawyer: Mintz ranks among the top 100 US law firms in terms of gross revenue.
Share by: